Anti-neuronal and stress-induced-phosphoprotein 1 antibodies in neuro-Behçet's disease

Vural, Burçak; Uğurel, Elif; Tüzün, Erdem; Kürtüncü, Murat; Zuliani, Luigi; Çavuş, Filiz; İçöz, Sema; Erdağ, Ece; Gül, Ahmet; Güre, Ali O.; Vincent, Angela; Özbek, Uğur; Eraksoy, Mefküre; Akman‐Demir, Gülşen

doi:10.1016/j.jneuroim.2011.08.008

Cited by 26 publications

(14 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…39 Inhibition of this interaction leads to impaired memory formation in rodents. 40 A recent report also describes the presence of autoantibodies to STIP1 in the blood and CSF of patients with neuro-Behçet's disease, 41 a chronic recurrent inflammatory disorder with central nervous system involvement that occurs in 5–10% of Behçet's disease patients. 41 …”

Section: Discussionmentioning

confidence: 99%

Autism-specific maternal autoantibodies recognize critical proteins in developing brain

Krakowiak²,

et al. 2013

View full text Add to dashboard Cite

Autism spectrum disorders (ASDs) are neurodevelopmental in origin, affecting an estimated 1 in 88 children in the United States. We previously described ASD-specific maternal autoantibodies that recognize fetal brain antigens. Herein, we demonstrate that lactate dehydrogenase A and B (LDH), cypin, stress-induced phosphoprotein 1 (STIP1), collapsin response mediator proteins 1 and 2 (CRMP1, CRMP2) and Y-box-binding protein to comprise the seven primary antigens of maternal autoantibody-related (MAR) autism. Exclusive reactivity to specific antigen combinations was noted in 23% of mothers of ASD children and only 1% of controls. ASD children from mothers with specific reactivity to LDH, STIP1 and CRMP1 and/or cypin (7% vs 0% in controls; P<0.0002; odds ratios of 24.2 (95% confidence interval: 1.45–405)) had elevated stereotypical behaviors compared with ASD children from mothers lacking these antibodies. We describe the first panel of clinically significant biomarkers with over 99% specificity for autism risk thereby advancing our understanding of the etiologic mechanisms and therapeutic possibilities for MAR autism.

show abstract

Section: Discussionmentioning

confidence: 99%

Autism-specific maternal autoantibodies recognize critical proteins in developing brain

Krakowiak²,

et al. 2013

View full text Add to dashboard Cite

show abstract

“…STIP1 is a major ligand of the cellular prion protein: this interaction stimulates neurogenesis in cultured hippocampal neurons and its inhibition yields impaired memory formation in rodents (Coitinho et al, 2007). Anti-STIP1 autoantibodies have been detected in blood and cerebrospinal fluid (CSF) of patients with neuro-Behcet’s disease (Vural et al, 2011). Finally, YBX1 (also known as p50) is critically involved in the cell motility and migration required for successful neural tube formation; most importantly, YBX1 acts as a DNA- and RNA-binding protein with chaperone properties, interacting with MeCP2 and FMRP, notoriously involved in most forms of Rett and Fragile-X syndrome, respectively (Eliseeva et al, 2011).…”

Section: Discussionmentioning

confidence: 99%

Anti-brain antibodies are associated with more severe cognitive and behavioral profiles in Italian children with Autism Spectrum Disorder

Piras

Haapanen

Napolioni

et al. 2014

Brain, Behavior, and Immunity

View full text Add to dashboard Cite

Circulating 45 and 62 kDa antibodies targeting the cerebellum were previously associated with Autism Spectrum Disorder (ASD), lower adaptive/cognitive function and aberrant behaviors. Moreover, 37, 39 and 73 kDa maternal antibodies (mAb) targeting the fetal brain were previously correlated with broad autism spectrum, irritability, abnormal brain enlargement and impaired expressive language. The present study aims towards clinically characterizing individuals with brain-targeted IgG and/or exposed to maternal antibrain antibodies in a large sample of Italian autistic children (N = 355), their unaffected siblings (N = 142) and mothers (N = 333). The presence of patient- and mother-produced anti-brain antibodies does not confer increased risk of autism within the same sibship. However, the 45 and 62 kDa antibodies are correlated with autism severity: the 45 kDa Ab is associated with cognitive impairment and lower scores at the Vineland Adaptive Behavior Scales, the 62 kDa Ab with motor stereotypies, while both correlate with larger head circumference (all P < 0.05). On the other hand, maternal 37, 39 and 73 kDa antibrain antibodies, either alone or in combination, are correlated with impaired verbal and non-verbal language development, neurodevelopmental delay and sleep/wake cycle disturbances in their autistic children (P < 0.05). Presence of the 62 kDa autoAb in the child is significantly associated with presence of the 39 and/or 73 kDa antibodies in his/her mother. Our results confirm and extend previous observations in an ethnically distinct sample, providing further evidence of a pathomorphic role for antibrain antibodies in autism while demonstrating their familial clustering.

show abstract

“…Moreover, BD and neuro-Behçet's disease (NBD) patients show more prominent antibody and T cell responses to various HSPs (e.g., HSP60, HSP70, etc.) than patients with other autoimmune neurological disorders [10,11]. These findings suggest that the autoimmune response triggered by HSPs expressed by bacteria might initiate inflammation through molecular mimicry ultimately giving rise to a multisystemic autoinflammatory disorder such as BD.…”

Section: Pathogenesismentioning

confidence: 87%

Behçet’s Disease and Nervous System Involvement

Kürtüncü

Tüzün

Akman‐Demir

2016

Curr Treat Options Neurol

Self Cite

View full text Add to dashboard Cite

Management of neuro-Behçet's disease can be divided into two stages: treatment of acute attacks and prevention of relapses. Treatment of acute attacks is accomplished by high-dose intravenous corticosteroids followed by maintenance treatment with oral steroids for 6-12 months depending on the type and severity of the neurological involvement. Relapses can be prevented by using immunosuppressants. Oral immunosuppressants such as azathioprine and mycophenolate are the most widely utilized agents for this purpose. Patients who are refractory or who cannot tolerate these medications can be managed by cyclophosphamide, interferon alpha, or anti-TNF-α monoclonal antibodies such as infliximab, etanercept, and adalimumab. Recent reports showed that newer agents such as tocilizumab, canakinumab, and anakinra, which exert their biological activity through IL-1 and IL-6 pathways, are also promising treatment alternatives for progressive or relapsing patients.

show abstract

Anti-neuronal and stress-induced-phosphoprotein 1 antibodies in neuro-Behçet's disease

Cited by 26 publications

References 26 publications

Autism-specific maternal autoantibodies recognize critical proteins in developing brain

Autism-specific maternal autoantibodies recognize critical proteins in developing brain

Anti-brain antibodies are associated with more severe cognitive and behavioral profiles in Italian children with Autism Spectrum Disorder

Behçet’s Disease and Nervous System Involvement

Contact Info

Product

Resources

About